Differences in treatment choices for localised prostate cancer diagnosed in private and public health services.

CONCLUSION: Prostate cancer treatment choices differ substantially between men diagnosed in private and public health services in Victoria. These differences are not explained by disease severity or comorbidity. PMID: 32996611 [PubMed - as supplied by publisher]
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research

Related Links:

CONCLUSION: PDR salvage brachytherapy in local recurrent previously irradiated prostate cancer is efficient with low late toxicity. Salvage-brachytherapy represents a valuable therapeutic option for the treatment of previously irradiated locally recurrent prostate cancer. PMID: 32593646 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
1247Background: While the diagnostic performance of 18F-FACBC PET/CT imaging in the restaging of patients with biochemical recurrence (BCR) after initial prostatectomy is well documented, its clinical utility in patients with BCR following primary non-prostatectomy treatments is unknown. We aimed to determine detection rate of 18F-FACBC PET/CT scan and the patterns of prostate cancer recurrence in patients with suspected BCR after initial non-prostatectomy treatments, particularly in patients with PSA levels below the accepted Phoenix definition of PSA failure (PSA nadir + 2). Methods: In this single tertiary institution s...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: GU - non-PSMA imaging (Poster Session) Source Type: research
Prostate cancer therapies are improving over time. But how do the long-term side effects from the various options available today compare? Results from a newly published study are providing some valuable insights. Investigators at Vanderbilt University and the University of Texas MD Anderson Cancer Center spent five years tracking the sexual, bowel, urinary, and hormonal status of nearly 2,000 men after they had been treated for prostate cancer, or monitored with active surveillance (which entails checking the tumor periodically and treating it only if it begins to grow). Cancers in all the men were still confined to the p...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Prostate Knowledge Treatments HPK Source Type: blogs
The age-old question in prostate cancer is which treatment is better, radical prostatectomy (RP) or external beam radiation therapy (EBRT)? Typically, RP failed at the margins of resection, whereas EBRT failed at the site of origin, and survival rates were the same. However, with low-dose rate (LDR) brachytherapy (BT), one can deliver high, ablative doses to the prostate, while also covering the edges, thereby capturing the best of both worlds.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
ConclusionEBRT  + BT was associated with a significantly better prostate CSS compared with surgery or EBRT. EBRT alone was inferior to surgery by OS.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
To compare 10-year oncologic treatment outcomes of radical prostatectomy (RP) vs external beam radiation therapy (EBRT) vs brachytherapy (BT) for patients with intermediate risk prostate cancer (IRPC).
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
In this study we evaluate the lesion detection efficacy of18F-DCFPyL PET/CT in patients with BCR and determine the detection efficacy as a function of their PSA value.MethodsA total of 248 consecutive patients were evaluated and underwent scanning with18F-DCFPyL PET/CT for BCR between November 2016 and 2018 in two hospitals in the Netherlands. Patients were examined after radical prostatectomy (52%), external-beam radiation therapy (42%) or brachytherapy (6%). Imaging was performed 120  min after injection of a median dose of 311 MBq18F-DCFPyL.ResultsIn 214 out of 248 PET/CT scans (86.3%), at least one lesion sug...
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
CONCLUSIONS: In this systematic review and meta-analysis, we did not observe higher rate of BCR after TRT for nonmetastatic CaP patients after definitive local therapy. Based on these data, others and we have outlined a phase I/II trial assessing the safety and benefits of TRT in select men with secondary symptomatic hypogonadism who have no active disease after definitive local CaP therapy with curative intent. PMID: 31296421 [PubMed - as supplied by publisher]
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
Publication date: Available online 4 June 2019Source: European UrologyAuthor(s): Sebastian Berg, Alexander Cole, Quoc-Dien Trinh
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 23 May 2019Source: European UrologyAuthor(s): Michael Froehner, Christian Thomas
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Australia Health | Brachytherapy | Cancer | Cancer & Oncology | External Beam Therapy | General Medicine | International Medicine & Public Health | Pathology | Prostate Cancer | Prostatectomy | Radiation Therapy | Urology & Nephrology